Scribe Therapeutics, a Phase 1 biotech developing CRISPR genetic therapies for high cholesterol, raised $129 million by offering 8.6 million shares at $15, the high end of the $13 to $15 range. The company offered 1.4 million more shares than anticipated. Existing shareholder Eli Lilly intends to purchase shares in the offering that together with its existing holdings would result in a post-IPO stake of 10.9%. The company also plans to raise an additional $7.5 million in a concurrent private placement to Sanofi.
Scribe Therapeutics is developing in vivo CRISPR-based therapies aimed at extending healthy lifespan through disease prevention, with an initial focus on cardiovascular and metabolic disease. Its lead candidate, STX-1150, uses an epigenetic silencing approach to durably lower LDL-C by repressing PCSK9 expression, without permanently altering DNA. It's currently in a first-in-human trial in Australia under TGA clearance, with initial data expected in the first half of 2027. Two follow-on programs, STX-1200 and STX-1400, apply the company's XE gene-editing technology to target Lp(a) and triglycerides as additional drivers of atherosclerotic cardiovascular disease, and are supported in part by CIRM grant funding, with Phase 1 trials anticipated in 2027 and 2028.
The Alameda, CA-based company will trade on the Nasdaq under the symbol SCTX. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities acted as joint bookrunners on the deal.
Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range
July 24, 2026

